So despite the success of HIV drugs and PrEP, precarious health-care systems and high drug costs mean we can't rely on them ...

The elimination of the latent viral reservoir remains the main barrier in the quest for a cure for people with HIV (PWH). The administration of latency reversal agents (LRA) at antiretroviral ...

Global health leaders and advocates challenged attendees of IAS to support the work of the partnerships that are creating patient-focused innovations for HIV prevention and treatment.

The global hunt for an HIV cure remains a puzzle, despite nearly 40 years of research and progress in treatment and prevention. Scientists have struggled largely because of the virus's ability ...

In early 2025, the US decision to halt foreign aid for HIV/AIDS programs triggered global concerns about a potential ...

How will the Trump administration's cuts to HIV research impact the progress that's been made towards ending the epidemic in the U.S.?

Gilead Sciences (GILD) stock in focus as the company joins The Global Fund to expand access to lenacapavir, an HIV PrEP ...

The drug, in June, received FDA approval as the first twice-yearly pre-exposure prophylaxis (PrEP) option to reduce the risk ...

This discovery could make treatment for an eye disease affecting millions with diabetes more accessible and affordable.

Lopinavir-induced Zmpste24 inhibition compromised nuclear membrane stability, reducing the interaction between the nuclear membrane-binding protei ...

More treatment facilities have been established in Eastern Visayas in response to the rising number of human immunodeficiency ...